Abstract
Background: The objective of the study was to compare the treatment outcomes in patients with occult primary carcinoma with axillary lymph node metastasis who were treated with mastectomy or with intent to preserve the breast.
Methods: From 1951 to 1998, 479 female patients were registered with axillary lymph node metastasis from an unknown primary. After clinical workup, including mammography, 45 patients retained this diagnosis and received treatment for T0 N1–2 M0 carcinoma of the breast. Clinical and pathological data were collected retrospectively, and survival was calculated from the date of initial diagnosis using the Kaplan-Meier method. Median follow-up time was 7 years.
Results: Median age was 54 years (range, 32–79). Clinical nodal status was N1 in 71% and N2 in 29% of the patients. Surgical treatment was mastectomy in 29% and an intent to preserve the breast in 71% of the patients. Locoregional radiotherapy was used in 71% and systemic chemoendocrine therapy was used in 73% of the patients. Of the 13 mastectomy patients, only one had a primary tumor discovered in the specimen. Two patients (4%) were ultimately diagnosed with lung cancer and neuroendocrine tumor. No significant difference was detected between mastectomy and breast preservation in locoregional recurrence (15% versus 13%), distant metastases (31% versus 22%), or 5-year survival (75% vs. 79%). Regardless of surgical therapy, the most important determinant of survival was the number of positive nodes. Five-year overall survival was 87% with 1–3 positive nodes compared with 42% with ≥4 positive nodes (P < .0001).
Conclusions: Occult primary carcinoma with axillary metastases can be treated with preservation of the breast without a negative impact on local control or survival.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
REFERENCES
Abbruzzese A, Abbruzzese M, Hess K, Raber M, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12: 1272–80.
Hainsworth J, Greco F. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993; 329: 257–63.
Tench DW, Page DL. The unknown primary presenting with axillary lymphadenopathy.In: Bland KI, Copeland EM, eds. The Breast: Comprehensive Management of Benign and Malignant Diseases, vol 2. 2nd ed. Philadelphia: W.B. Saunders, 1998: 1447–52.
Owen HW, Dockerty MB, Gray HK. Occult carcinoma of the breast. Surg Gynecol Obstet 1954; 98: 302–8.
Rosen PP. Axillary lymph node metastases in patients with occult noninvasive breast carcinoma. Cancer 1980; 46: 1298–1306.
Patel J, Nemoto T, Rosner D, Dao TL, Pickren JW. Axillary lymph node metastasis from an occult breast cancer. Cancer 1981; 47: 2923–27.
Halsted W. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907; 46: 1–19.
Cameron HC. Some clinical facts regarding mammary cancer. BMJ 1909; 1: 577–82.
Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases: Updated management. Arch Surg 1990; 125: 210–14.
Hainsworth JC, Greco FA. Management of patients with cancer of unknown primary site. Oncology 2000; 14: 563–79.
Morrow M, Schmidt RA, Bucci C. Breast conservation for mammographically occult carcinoma. Ann Surg 1998; 227: 502–6.
Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, McNeese M. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 1990; 66: 1461–1467.
American Joint Committee on Cancer. Breast.In: AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989; 12: 123–28.
Buzdar AU, Hortobagyi GN, Kau SW, et al. Breast cancer adjuvant therapy at the M.D. Anderson Cancer Center: Results of four prospective studies.In: Salmon SE, ed. Adjuvant Therapy of Cancer VII. Philadelphia: JB Lippincott Company, 1993: 220–25.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 185: 1457–81.
Fortunato L, Sorrento JJ, Golub RA. Occult breast cancer: A case report and review of the literature. N Y State J Med 1992; 92: 555–57.
Meterissian S, Fornage BD, Singletary SE. Clinically occult breast carcinoma: Diagnostic approaches and role of axillary node dissection. Ann Surg Oncol 1995; 2: 314–18.
Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: A follow-up of 48 patients. Hum Pathol 1990; 21: 518–23.
van Ooijen B, Bontenbal M, Henzen-Logmans SC. Axillary nodal metastases from an occult primary consistent with breast carcinomas. Br J Surg 1993; 80: 1299–1310434_2001_Article_425.
Feigenberg Z, Zer M, Dintsman M. Axillary metastases from an unknown primary source: A diagnostic and therapeutic approach. Isr J Med Sci 1976; 12: 1151–58.
Merson M, Andreola S, Galimberti V, Bufalino R, Marchini S, Veronesi U. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 1992; 70: 504–8.
Campana F, Fourquet A, Ashby MA, et al. Presentation of axillary lymphadenopathy without detectable primary (T0N1b breast cancer): Experience at Institut Curie. Radiother Oncol 1989; 15: 321–5.
Fourquet A, De la Rochefordiere A, Campana F. Occult primary cancer with axillary metastases.In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999: 703–7.
Vilcoq JR, Calle R, Ferme F, Veith F. Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch Surg 1982; 117: 1136–38.
Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 1980; 45: 2917–24.
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181–7.
Henderson IC, Berry D, Demetri G, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 1998; 17: 390a
Gianni L, Capri G, Valagussa P, Bonadonna G. Putting taxanes to work in2 operable breast cancer: A search for selective indications from empirical studies. Recent Results Cancer Res 1998; 152: 314–22.
Nabholtz JM, Mackey J, Smylie M, Tonkin K. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer. Semin Oncol 1998; 25: 27–31.
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998; 351: 1451–67.
Anonymous. NSABP halts B-14 trial: No benefit seen beyond 5 years of tamoxifen use (news). J Natl Cancer Inst 1995; 87: 1829.
Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005–18.
International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15: 1385–94.
Griem KL, Henderson C, Gelman R, et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 1987; 5: 1546–55.
Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334: 1356–61.
Buzdar A, Kau S, Smith T, et al. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer 1993; 71: 3680–84.
Leonard CE, Wood ME, Zhen B, et al. Does administration of chemotherapy prior to radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J Clin Oncol 1995; 13: 2906–15.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vlastos, G., Jean, M.E., Mirza, A.N. et al. Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases. Ann Surg Oncol 8, 425–431 (2001). https://doi.org/10.1007/s10434-001-0425-6
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-001-0425-6